SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing intense scrutiny and high volatility after a clinical hold was placed on its gene therapies, RGX-111 and RGX-121, due to a patient developing a brain tumor, leading to widespread community speculation about an impending Complete Response Letter for RGX-121's imminent PDUFA decision.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending due to strong preliminary financial results and significantly raised growth outlook, driven by robust demand for its AI data center connectivity solutions from major hyperscalers. The community is actively discussing its valuation and the ongoing relevance of its copper-based technology amidst recent market volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is rallying on community excitement around imminent EU approval for its cancer therapeutic, Anktiva, and intensified discussions of an 'Immunotherapy 2.0' partnership with Saudi Arabia for broad cancer indications. Investors are anticipating a significant short squeeze, validating the company's undervalued platform against recent industry acquisitions and its mission to deliver 'unstoppable' cancer treatments.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as recent weak guidance for the coming quarter has driven a sell-off and ignited community debate over decelerating automotive and industrial demand. While bears foresee further drops, bulls are underscoring the company's strategic pivot to AI data centers with a significant Nvidia partnership and a large share repurchase program.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending following its strong earnings beat, raised guidance, and a new share repurchase program, which are driving renewed bullish sentiment and analyst upgrades. Community discussion centers on its perceived undervaluation and potential for a short squeeze, as the company emphasizes strategic AI innovations within the evolving gig economy.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending following its earnings report, sparking community discussion over a notable stock decline despite positive EPS growth and reaffirmed guidance, with many attributing the dip to revenue shifts while maintaining strong long-term confidence in its extensive backlog of critical government, defense, and nuclear contracts.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing intense discussion after halting its compounded GLP-1 weight loss pill amid a patent infringement lawsuit from Novo Nordisk and increased FDA scrutiny, creating a sharp divide among investors debating a potential short squeeze against fundamental concerns over regulatory and legal risks.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

AMKOR Technology is trending after exceeding recent earnings and revenue expectations, driven by strong demand for advanced packaging in AI solutions. While current performance is strong, community discussions highlight concerns over future gross margin guidance and substantial capital expenditures, even as the company expands its role in US semiconductor manufacturing.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending sharply lower following the abrupt departures of its CFO and General Counsel amid an accounting review and delayed financial filings, sparking intense community discussion about whether the significant sell-off is an extreme overreaction or indicative of severe internal control issues.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is a top trending stock, buoyed by recent analyst upgrades and its pivotal role in the rapidly expanding AI data center infrastructure. The community is highly focused on its essential high-speed connectivity solutions, strategic optical technology acquisitions, and potential for significant growth driven by hyperscaler spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned an average rating of "Hold" from the twenty-eight brokerages that are presently covering the stock, Marketbeat.com...

Y Intercept Hong Kong Ltd Lowers Position in Sarepta Therapeutics, Inc. $SRPT

Y Intercept Hong Kong Ltd cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 91.0% during the 3rd quarter, according to the company in its most recent Form 13F...

Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags

Sarepta Therapeutics (NASDAQ:SRPT) reported three-year top-line results from its EMBARK Phase 3 pivotal trial evaluating ELEVIDYS, highlighting what executives described as the first large...

SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD 

SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.

HC Wainwright Reiterates Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)

HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a research note on Tuesday...

Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday

Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?

Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 13.9% on Analyst Upgrade

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 13.9% After Analyst Upgrade...

Is KROS' KER-065 the Next Breakthrough in DMD Space?

KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.

<ul class="summary-bullets"><li>The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group.</li><li>ELEVIDYS reduced the rate of functional decline by about 70%.</li><li>ELEVIDYS has been administered to more than 1,200 patients worldwide in both clinical trials and real-world use.</li></ul>Shares of Sarepta Therapeutics (SRPT) jumped 6% in pre-market trading on Monday after the company announced positive three-year topline results from its Phase 3 EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with Duchenne Muscular Dystrophy (DMD).SRPT shares gained further after the opening bell, trading 12% higher at the time of writing.The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group. Three years after treatment, patients maintained North Star Ambulatory Assessment (NSAA) scores above baseline, while untreated patients showed the expected decline.ELEVIDYS reduced the rate of functional decline by about 70% or more on key measures, including Time to Rise and the 10-meter walk/run, with the treatment effect increasing over time. No new safety concerns were identified, supporting ELEVIDYS’ manageable safety profile.Sarepta said analysis of its three-year data is ongoing and includes functional results from patients who crossed over to treatment and have now been followed for two years.&nbsp;ELEVIDYS is currently the only approved gene therapy for DMD and has been given to more than 1,200 patients worldwide in both clinical trials and real-world use. The therapy is available for ambulatory patients aged four and older under an updated FDA label announced in late 2025.&nbsp;<h2 class="st-heading-2">Latest Updates</h2>Sarepta is working with Roche to broaden global access to the therapy, with Sarepta handling U.S. regulatory approval, manufacturing, and commercialization, and Roche managing approvals and distribution outside the United States.Earlier this month, the company announced the submission of a clinical trial application to New Zealand’s Medsafe for its INSIGHTT study of SRP-1005, an investigational small interfering RNA (siRNA) therapy for Huntington’s disease. If approved, the first-in-human trial is expected to begin in the second quarter of 2026.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ amid ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/SRPT">SRPT</a> was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/srpt_jpg_4e3ede4352.webp" alt="srpt.jpg">One bullish user said the ‘results are very impressive for a rare disease with no cure’.<stembedurl>https://stocktwits.com/free2dream/message/642864936</stembedurl>Another user added that breaking the $25 resistance mark would be huge. The stock is currently trading around $23.5.<stembedurl>https://stocktwits.com/Sareptaking/message/642878594</stembedurl>The stock has been under heavy selling pressure over the past year, declining more than 80%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/traw-stock-slides-in-volatile-session-after-covid-19-treatment-trial-update/cmy7u2BR4hI">TRAW Stock Slides In Volatile Session –&nbsp; What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did SRPT Stock Rise 6% In Pre-Market Today?

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.   

SRPT Pre-Market Rally Fueled By Promising DMD Therapy Results

Equity

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.

 

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$18.31
Prev Close	$18.50
Open	$18.36
Dividend Yield	0.00%
50-Day Moving Average	$21.39
Beta	1.14
Avg. Volume	3.18M
PE Ratio	-6.40

52-Week High	$114.41
52-Week Low	$10.42
Market Capitalization	$1.94B
EPS (Annual)	$2.34
Price to Book	1.47
Revenue Per Employee	$1.39M
Enterprise Value/EBITDA	N/A

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News

SRPTSarepta Therapeutics Inc